✕
For Patients & Families
Our Science
Connect with Us
March 2025: American Academy of Allergy, Asthma, and Immunology and World Allergy Organization Joint Congress
Treatment with Navenibart (STAR-0215) Reduces Attack Severity and Use of Rescue Medication in Patients with Hereditary Angioedema (HAE): Interim Results from the ALPHA-STAR Trial
March 2025: American Academy of Allergy, Asthma, and Immunology and World Allergy Organization Joint Congress
ALPHA-ORBIT – A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Navenibart in Adolescent and Adult Participants with Type 1 and Type 2 Hereditary Angioedema (HAE)
March 2025: American Academy of Allergy, Asthma, and Immunology and World Allergy Organization Joint Congress
Preclinical Data Supporting the Differentiated Profile of STAR-0310, a Novel OX40 Antagonistic Monoclonal Antibody
February 2025: Western Society of Allergy, Asthma & Immunology Annual Scientific Session
Navenibart (STAR-0215) Induces Rapid Improvements of Quality of Life in HAE Patients in the ALPHA-STAR Trial
November 2024: Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting
Quality of Life (QoL) Improvements in Patients With Hereditary Angioedema (HAE); Interim Results From the Phase 1b/2 ALPHA-STAR Clinical Trial
October 2024: American College of Allergy, Asthma & Immunology Annual Scientific Meeting
Navenibart (STAR-0215) Induces Rapid Improvements of Quality of Life in HAE Patients in the ALPHA-STAR Trial
October 2024: American College of Allergy, Asthma & Immunology Annual Scientific Meeting
Quality of Life and Burden of Disease in Patients With Hereditary Angioedema and Their Caregivers
October 2024: Global Angioedema Forum
ALPHA-STAR, a Phase 1b/2 Clinical Trial of Single and Multiple Doses of Navenibart (STAR-0215) in Patients with Hereditary Angioedema: Interim Safety and Efficacy Outcomes
October 2024: Global Angioedema Forum
Rationale and Design of the ALPHA-SOLAR Clinical Trial of Navenibart (STAR-0215) for the Treatment of Hereditary Angioedema (HAE)
September 2024: European Academy of Dermatology and Venerology
ALPHA-STAR, a Phase 1b/2 Clinical Trial of Single and Multiple Doses of STAR-0215 in Patients with Hereditary Angioedema: Initial Safety and Efficacy Outcomes
